Rohto Pharmaceutical Co (TSE:4527) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4527 Rohto Pharmaceutical Co Ltd TSE:4527
83 GF Score
Price 円2,483.50
GF Value 円3,479.27
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Rohto Pharmaceutical Co Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

TSE:4527
83GF Score
Rohto Pharmaceutical Co Ltd TSE:4527
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rohto Pharmaceutical Co (TSE:4527) Overvalued in 2026?

Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued. The current stock price of 円2,483.50 is trading 28.6% below its estimated GF Value™ of 円3,479.27. GuruFocus considers Rohto Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4527:

  • Dividends Received:
  • GF Value™: 円3,479.27 vs. price of 円2,483.50 (28.6% below fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the TSE:4527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rohto Pharmaceutical Co Business Description

Other Exchanges RPHCF:USAUC1:Germany
Address 1-8-1 Tatsuminishi, Ikuno-ku, Osaka, JPN, 544-8666
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
83GF Score

Get the complete analysis for TSE:4527

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,483.50
Price
円3,479.27
GF Value